公开(公告)号：US5580559A

公开(公告)日：1996-12-03

申请号：US311848

申请日：1994-09-23

Applicant: Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

Inventor： Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

IPC: C07K14/735 ,  C12N9/72 ,  C12N15/67 ,  C12N15/85 ,  A61K38/49 ,  C12N9/48 ,  C12N9/64

CPC classification number: C12N9/6456 ,  C07K14/70535 ,  C12N15/67 ,  C12N15/85 ,  C07K2319/00 ,  C07K2319/02 ,  C12N2800/108 ,  C12N2830/002 ,  C12N2830/702

Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Abstract translation: 具有由至少两个对应于人t-PA和人u-PA的氨基酸同一性和数量与子序列的亚序列组成的氨基酸序列的新型单链杂交纤维蛋白溶酶原激活物及其突变体，其中至少一个N 糖基化位点被修饰，使得在这些位点不能发生糖基化显示出有价值的药理学性质。 混合型纤溶酶原激活物是通过重组DNA技术产生的。

公开(公告)号：US5242819A

公开(公告)日：1993-09-07

申请号：US808936

申请日：1991-12-13

Applicant: Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

Inventor： Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

IPC: C07K14/735 ,  C12N9/72 ,  C12N15/67 ,  C12N15/85

CPC classification number: C12N9/6456 ,  C07K14/70535 ,  C12N15/67 ,  C12N15/85 ,  C07K2319/00 ,  C07K2319/02 ,  C12N2800/108 ,  C12N2830/002 ,  C12N2830/702

Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Abstract translation: 具有由至少两个对应于人t-PA和人u-PA的氨基酸同一性和数量与子序列的亚序列组成的氨基酸序列的新型单链杂交纤维蛋白溶酶原激活物及其突变体，其中至少一个N 糖基化位点被修饰，使得在这些位点不能发生糖基化显示出有价值的药理学性质。 混合型纤溶酶原激活物是通过重组DNA技术产生的。

公开(公告)号：US20120027720A1

公开(公告)日：2012-02-02

申请号：US13168734

申请日：2011-06-24

Applicant: Amir TAMIZ ,  Sefik Alkan

Inventor： Amir TAMIZ ,  Sefik Alkan

IPC: A61K38/08 ,  A61K38/07 ,  A61P3/10 ,  A61K39/385 ,  A61K39/395 ,  A61K38/20 ,  A61K38/18 ,  C07K17/00 ,  A61P35/00

CPC classification number: A61K47/64

Abstract: The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide conjugate of the invention, optionally.

Abstract translation: 本发明提供了新的肽缀合物。 本发明的肽结合物可用作治疗剂。 肽共轭物发明也可用于递送一种或多种另外的活性剂。 本发明还提供了通过向患有该疾病的受试者施用包含本发明的肽缀合物的组合物，任选地来治疗疾病的方法。

公开(公告)号：US5071761A

公开(公告)日：1991-12-10

申请号：US381444

申请日：1989-07-18

Applicant: Francois Meyer ,  Albert Hinnen ,  Andreas Meister ,  Markus G. Grutter ,  Sefik Alkan

Inventor： Francois Meyer ,  Albert Hinnen ,  Andreas Meister ,  Markus G. Grutter ,  Sefik Alkan

IPC: A61K38/00 ,  A61K38/21 ,  A61K39/395 ,  A61P31/12 ,  A61P35/00 ,  C07H21/04 ,  C07K1/22 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K14/52 ,  C07K14/555 ,  C07K14/56 ,  C07K16/00 ,  C07K16/24 ,  C07K19/00 ,  C12N1/19 ,  C12N1/21 ,  C12N15/00 ,  C12N15/09 ,  C12N15/20 ,  C12P21/00 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  C12R1/865 ,  C12R1/91

CPC classification number: C07K16/249 ,  C07K14/56 ,  A61K38/00 ,  Y10S930/142

Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.

公开(公告)号：US20060142202A1

公开(公告)日：2006-06-29

申请号：US11360071

申请日：2006-02-23

Applicant: Sefik Alkan ,  William Kieper ,  John Vasilakos ,  Jason Bonk ,  George Griesgraber ,  Kenneth Lipson ,  Jie Liu ,  James Mendoza ,  Doris Stoermer ,  Paul Wightman ,  Naiyong Jing ,  William Schultz

Inventor： Sefik Alkan ,  William Kieper ,  John Vasilakos ,  Jason Bonk ,  George Griesgraber ,  Kenneth Lipson ,  Jie Liu ,  James Mendoza ,  Doris Stoermer ,  Paul Wightman ,  Naiyong Jing ,  William Schultz

IPC: A61K38/09 ,  A61K31/4745

CPC classification number: A61K31/4745 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851

Abstract: The present invention provides immunomodulatory compositions include an immune response modifier moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the subject an immunomodulatory composition that includes an immune response modifier moiety coupled to a targeting moiety that recognizes a delivery target.

Abstract translation: 本发明提供免疫调节组合物包括与靶向部分偶联的免疫应答调节剂部分。 在另一方面，本发明提供了提供IRM的靶向递送，产生局部免疫应答和治疗受试者的病症的方法。 通常，所述方法包括向受试者施用免疫调节组合物，其包含与识别递送目标的靶向部分偶联的免疫应答调节剂部分。

公开(公告)号：US06342373B1

公开(公告)日：2002-01-29

申请号：US07707265

申请日：1991-05-24

Applicant: Hans Rink ,  Manfred Liersch ,  Peter Sieber ,  Werner Rittel ,  Francois Meyer ,  Ursula Seemüller ,  Hans Fritz ,  Walter Märki ,  Sefik Alkan

Inventor： Hans Rink ,  Manfred Liersch ,  Peter Sieber ,  Werner Rittel ,  Francois Meyer ,  Ursula Seemüller ,  Hans Fritz ,  Walter Märki ,  Sefik Alkan

IPC: C12N1509

CPC classification number: C07K16/38 ,  A61K2039/505

Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.

Abstract translation: 本发明涉及编码eglin的DNA序列，含有这样的DNA序列的表达质粒，用这种表达质粒转化的宿主，由这样的转化宿主产生的新的eglin化合物，产生此类抗体的杂交瘤细胞， 含有此类抗体的免疫测定法，以及其制备方法以及借助于转化的宿主制备埃可林的方法。 可根据本发明制备的胰蛋白酶具有有用的药理学性质。

公开(公告)号：US20050226878A1

公开(公告)日：2005-10-13

申请号：US11142045

申请日：2005-06-01

Applicant: Mark Tomai ,  Gary Gullikson ,  David Hammerbeck ,  Elaine Egging ,  Michael Reiter ,  Christopher Gram ,  John Vasilakos ,  Sefik Alkan

Inventor： Mark Tomai ,  Gary Gullikson ,  David Hammerbeck ,  Elaine Egging ,  Michael Reiter ,  Christopher Gram ,  John Vasilakos ,  Sefik Alkan

IPC: A61K31/4745 ,  A61K31/573 ,  A61K39/395

CPC classification number: A61K45/06

Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract translation: 本发明提供包括免疫应答调节剂（IRM）组分和抗炎组分的治疗组合。 本发明还提供了通过给予具有包括IRM组分和抗炎组分的治疗组合的患者的治疗病症的方法。

公开(公告)号：US4885166A

公开(公告)日：1989-12-05

申请号：US871059

申请日：1986-06-05

Applicant: Francois Meyer ,  Albert Hinnen ,  Andreas Meister ,  Markus G. Grutter ,  Sefik Alkan

Inventor： Francois Meyer ,  Albert Hinnen ,  Andreas Meister ,  Markus G. Grutter ,  Sefik Alkan

IPC: A61K38/00 ,  A61K38/21 ,  A61K39/395 ,  A61P31/12 ,  A61P35/00 ,  C07H21/04 ,  C07K1/22 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K14/52 ,  C07K14/555 ,  C07K14/56 ,  C07K16/00 ,  C07K16/24 ,  C07K19/00 ,  C12N1/19 ,  C12N1/21 ,  C12N15/00 ,  C12N15/09 ,  C12N15/20 ,  C12P21/00 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  C12R1/865 ,  C12R1/91

CPC classification number: C07K16/249 ,  C07K14/56 ,  A61K38/00 ,  Y10S930/142

Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.

Abstract translation: 分别产生衍生自属于干扰素αB和αD组的淋巴母细胞干扰素α-2和α-3的新型混合干扰素。 该新型混合干扰素具有有价值的抗病毒和抗增殖特性。

公开(公告)号：US4780401A

公开(公告)日：1988-10-25

申请号：US717738

申请日：1985-03-28

Applicant: Christoph Heusser ,  Rudolf H. Andreatta ,  Sefik Alkan ,  Jeanette Wood

Inventor： Christoph Heusser ,  Rudolf H. Andreatta ,  Sefik Alkan ,  Jeanette Wood

IPC: G01N33/573 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61P9/12 ,  C07K14/005 ,  C07K14/195 ,  C07K14/81 ,  C07K16/00 ,  C07K16/40 ,  C07K19/00 ,  C12N5/10 ,  C12N9/64 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/577 ,  G01N33/53 ,  C12N15/00

CPC classification number: C07K16/40 ,  A61K38/00 ,  Y10S435/81 ,  Y10S435/975 ,  Y10S436/808 ,  Y10S436/815 ,  Y10S530/808 ,  Y10S530/86

Abstract: The invention relates to novel monoclonal antibodies having a high affinity for human renin, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, and to processes for the preparation of said hybridoma cells lines. The monoclonal antibodies according to the invention and their derivatives can be used for the qualitative and quantitative determination of human renin and structurally similar renin, for the purification of human renin and structurally similar renin and for the treatment of high blood pressure and cardiac insufficiency.

Abstract translation: 本发明涉及对人肾素高亲和力的新型单克隆抗体，其衍生物，制备这些抗体及其衍生物的方法，产生这些抗体的杂交瘤细胞系以及制备所述杂交瘤细胞系的方法。 根据本发明的单克隆抗体及其衍生物可用于人肾素和结构相似的肾素的定性和定量测定，用于纯化人肾素和结构相似的肾素，并用于治疗高血压和心脏功能不全。

公开(公告)号：US08957032B2

公开(公告)日：2015-02-17

申请号：US12991658

申请日：2009-05-06

Applicant: Sefik Alkan ,  Amir Tamiz ,  Kelly Marie Kitchens ,  Malarvizhi Durai ,  Neil Poloso ,  Rosa A. Carrasco

Inventor： Sefik Alkan ,  Amir Tamiz ,  Kelly Marie Kitchens ,  Malarvizhi Durai ,  Neil Poloso ,  Rosa A. Carrasco

IPC: A61K38/00 ,  A61P1/04 ,  A61K38/04 ,  C07K7/06

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  C07K5/0804 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/081 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0817 ,  C07K5/0819 ,  C07K5/0821 ,  C07K5/1008 ,  C07K5/101

Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

Abstract translation: 鉴定了新型化合物和抑制生物屏障渗透性和抑制跨越生物屏障的肽易位的方法。 提供了用于确定生物屏障渗透性调节剂和穿过生物屏障的肽易位的测定。 提供了治疗与生物屏障渗透性异常有关的疾病和跨越生物屏障的肽易位的方法。 这些疾病包括乳糜泻，坏死性小肠结肠炎，糖尿病，癌症，炎性肠病，哮喘，COPD，过度或不良免疫反应，麸质敏感性，麸质过敏，食物过敏，类风湿性关节炎，多发性硬化，免疫介导或1型糖尿病 ，系统性红斑狼疮，牛皮癣，硬皮病和自身免疫性甲状腺疾病。